Pulmonary nodules in patients with melanoma--assume nothing.
Murphy F. et al, (2012), Ann Oncol, 23, 545 - 546
Tumor refractoriness to anti-VEGF therapy is mediated by myeloid cell recruitment in malignant melanoma
Helfrich I. et al, (2012), EXPERIMENTAL DERMATOLOGY, 21, e45 - e45
The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential.
Luc S. et al, (2012), Nat Immunol, 13, 412 - 419
Megakaryocytes, malignancy and bone marrow vascular niches.
Psaila B. et al, (2012), J Thromb Haemost, 10, 177 - 188
Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
Gillies RS. et al, (2012), Br J Surg, 99, 239 - 245
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
Dean E. et al, (2012), Br J Cancer, 106, 468 - 474
New challenges in endpoints for drug development in advanced melanoma.
Ribas A. et al, (2012), Clin Cancer Res, 18, 336 - 341
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Kirkwood JM. et al, (2012), Clin Cancer Res, 18, 555 - 567
Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer.
Li HK. et al, (2012), J Clin Oncol, 30, e19 - e20
Epithelial Ovarian Cancer
Gabra H. and Blagden S., (2012), Dewhurst's Textbook of Obstetrics & Gynaecology: Eighth Edition, 760 - 775
LARP1 Regulates the Site-specific Synthesis of Proteins Required for Cancer Cell Invasion and Migration
Mura M. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, S77 - S77
Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma
Soria JC. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 188 - 188
MNK 1 and 2 Inhibitors Are Active in Platinum-resistant Ovarian Cancer Cells
Mura M. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 26 - 26
Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model
Reckzeh K. et al, (2012), Leukemia, 26, 1527 - 1536
Multivariate screening of prognostic factors to identify a novel, simple, and objective marker to optimize patient selection and predict survival benefit in early-phase trials.
Stavraka C. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors
Gan H. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 189 - 189
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.
Coley HM. et al, (2012), Oncotarget, 3, 78 - 83
Use of inflammation-based scores to optimize the selection of patients with advanced cancer considered for early-phase clinical trials
Pinato DJ. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ. et al, (2011), N Engl J Med, 365, 2484 - 2496